Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Related Posts
Conn BM, Durazo-Arvizu R, Wong CF, West AE, Chen D, Chan YM, Ehrensaft D, Garofalo R, Hidalgo MA, Rosenthal SM, Olson-Kennedy J. Gender Minority Stress[...]
Sarkisian C, Ibrahim K, Vangala S, Villaflores CW, Cheng EM, Turner W, Leuchter RK, Machado A, Tabar J, Verdeflor JA, Purvis J, Goncharova A, Pletcher[...]
Wessel LE, Mefford MR, Ghosh D, Nelson SD, Christ AB, Russell M, Bernthal NM, Kendal JK. An Analysis of CT-Guided Percutaneous Core Needle Biopsy of[...]